A5008498660- Cannabis and Cannabinoid Research
- Neuroscience and Neuropharmacology Research
- Parkinson's Disease Mechanisms and Treatments
- Metabolism and Genetic Disorders
- Neurotransmitter Receptor Influence on Behavior
- GABA and Rice Research
- Receptor Mechanisms and Signaling
- Libraries, Manuscripts, and Books
- Cancer therapeutics and mechanisms
- Antibiotics Pharmacokinetics and Efficacy
- Pharmacological Receptor Mechanisms and Effects
- Drug Transport and Resistance Mechanisms
- Pancreatic function and diabetes
- Diet and metabolism studies
- Sleep and Wakefulness Research
- Olfactory and Sensory Function Studies
- Pharmacological Effects and Toxicity Studies
- Neurogenesis and neuroplasticity mechanisms
- E-Learning and Knowledge Management
- Mitochondrial Function and Pathology
- Educational Technology in Learning
- Thyroid and Parathyroid Surgery
- Respiratory Support and Mechanisms
- Diabetes and associated disorders
- Biotin and Related Studies
Hospital Universitario De Cabueñes
2025
Mexican Social Security Institute
2024
Hospital Universitari Sant Joan de Reus
2024
Hospital Universitario Miguel Servet
2009-2023
Universidad Complutense de Madrid
2013-2022
Instituto Ramón y Cajal de Investigación Sanitaria
2012-2022
Centro de Investigación Biomédica en Red
2010-2022
Biomedical Research Networking Center on Neurodegenerative Diseases
2012-2022
Instituto de Salud Carlos III
2020-2022
Hospital Universitario Puerto Real
2015-2021
BACKGROUND AND PURPOSE Previous findings have indicated that a cannabinoid, such as Δ 9 ‐THCV, which has antioxidant properties and the ability to activate CB 2 receptors but block 1 , might be promising therapy for alleviating symptoms delaying neurodegeneration in Parkinson's disease (PD). EXPERIMENTAL APPROACH The of ‐THCV reduce motor inhibition provide neuroprotection was investigated rats lesioned with 6‐hydroxydopamine mice lipopolysaccharide (LPS). KEY RESULTS Acute administration...
Background The transcription factor Nrf2 (NF-E2-related 2) and its target gene products, including heme oxygenase-1 (HO-1), elicit an antioxidant response that may have therapeutic value for Parkinson's disease (PD). However, HO-1 protein levels are increased in dopaminergic neurons of (PD) patients, suggesting participation free-iron deposition, oxidative stress neurotoxicity. Before targeting PD therapy it is imperative to determine if neurotoxic or neuroprotective the basal ganglia....
Neuroprotection with cannabinoids in Parkinson's disease (PD) has been afforded predominantly antioxidant or anti-inflammatory cannabinoids. In the present study, we investigated and neuroprotective properties of VCE-003.2, a quinone derivative non-psychotrophic phytocannabinoid cannabigerol (CBG), which may derive its activity at peroxisome proliferator-activated receptor-γ (PPARγ). The compound is also an antioxidant. We evaluated VCE-003.2 vivo [mice subjected to unilateral intrastriatal...
The antioxidant and CB2 receptor agonist properties of Δ9-tetrahydrocannabivarin (Δ9-THCV) afforded neuroprotection in experimental Parkinson's disease (PD), whereas its CB1 antagonist profile at doses lower than 5 mg/kg caused anti-hypokinetic effects. In the present study, we investigated anti-dyskinetic potential Δ9-THCV (administered i.p. 2 for two weeks), which had not been before. This objective was after inducing dyskinesia by repeated administration L-DOPA (i.p. 10 mg/kg) a genetic...
CONTRALATERAL rotations induced by the D1-like agonist SKF 38393 in unilaterally 6-hydroxydopamine-lesioned rats were completely prevented administration of antagonist SCH 23390. A similar result was obtained after intracerebroventricular an antisense oligodeoxynucleotide for D1 receptor (D1R-as). Contrariwise, a D5R-as potentiated effects 38393, showing 60% increase rotational scores. Both reversible upon cessation D1R-as or treatment and also specific since scores treated with vehicle...
In a recent study, we described the neuroprotective properties of VCE-003.2-an aminoquinone derivative non-psychotropic phytocannabinoid cannabigerol (CBG)-administered intraperitoneally (i.p.) in an inflammatory model Parkinson's disease (PD). We also demonstrated that these derive from its activity on peroxisome proliferator-activated receptor-γ, particular at regulatory site within this receptor type. present wanted to further confirm potential using oral lipid formulation VCE-003.2,...
The 3-hydroxyquinone derivative of the non-psychotrophic phytocannabinoid cannabigerol, so-called VCE-003.2, and some other derivatives have been recently investigated for neuroprotective properties in experimental models Parkinson’s disease (PD) mice. pharmacological effects those were related to activity on peroxisome proliferator-activated receptor-γ (PPAR-γ) possibly pathways. In present study, we VCE-004.8 (formulated as EHP-101 oral administration), cannabidiol (CBD), with agonist at...
This study was designed to examine the type of changes experienced by CB1 receptor, a key element cannabinoid signaling system, in basal ganglia different mouse mutants generated deletion specific genes associated with development Parkinson's disease humans [PARK1 (α-synuclein), PARK2 (parkin) or PARK6 (PINK1)]. We observed that receptor-mRNA levels were significantly reduced caudate-putamen three models under examination when animals analyzed at early phases (≤ 12 months age). decrease was,...
A 61-year-old male developed abdominal distension after ascending to an altitude of 4,000 meters, with radiological and endoscopic findings suggestive acute gastric ischemia. The patient was managed conservatively, a favorable clinical outcome.
Cannabinoids act as pleiotropic compounds exerting, among others, a broad-spectrum of neuroprotective effects. These effects have been investigated in the last years different preclinical models neurodegeneration, with cannabinoid type-1 (CB1) and type-2 (CB2) receptors concentrating an important part this research. However, issue has also extended to additional targets that are active for cannabinoids, such orphan G-protein receptor 55 (GPR55). In present study, we potential VCE-006.1,...
TO study the specific contribution of D3 dopamine receptor in generation locomotor activity, total or partially dopamine-depleted rats were pretreated with an antisense oligodeoxynucleotide for (D3R-as) and activity induced by apomorphine was measured. A 35.7% increase seen totally dopaminedepleted D3R-as, whereas same antisense, caused a significantly greater response (95%) compared control groups (pretreated vehicle). In situ autoradiography receptors showed 27% fall density islands...